Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In human cells oxygen levels are 'sensed' by a set of ferrous iron and 2-oxoglutarate dependent dioxygenases. These enzymes regulate a broad range of cellular and systemic responses to hypoxia by catalysing the post-translational hydroxylation of specific residues in the alpha subunits of hypoxia inducible factor (HIF) transcriptional complexes. The HIF hydroxylases are now the subject of pharmaceutical targeting by small molecule inhibitors that aim to activate or augment the endogenous HIF transcriptional response for the treatment of anaemia and other hypoxic human diseases. Here we consider the rationale for this therapeutic strategy from the biochemical, biological and medical perspectives. We outline structural and mechanistic considerations that are relevant to the design of HIF hydroxylase inhibitors, including likely determinants of specificity, and review published reports on their activity in pre-clinical models and clinical trials.

Original publication

DOI

10.1016/j.mam.2016.01.001

Type

Journal article

Journal

Molecular aspects of medicine

Publication Date

02/2016

Volume

47-48

Pages

54 - 75

Addresses

Centre for Cellular and Molecular Physiology, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom.

Keywords

Animals, Humans, Ischemia, Anemia, Disease Models, Animal, Inflammation, Oxygen, Mixed Function Oxygenases, Erythropoietin, Drug Delivery Systems, Protein Conformation, Hypoxia-Inducible Factor 1, Randomized Controlled Trials as Topic, Prolyl-Hydroxylase Inhibitors, Hypoxia